Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease

被引：19

作者：

Domingos, Sofia ^{[1
]}

Duarte, Teresa ^{[2
]}

Saraiva, Lucilia ^{[3
]}

Guedes, Rita C. ^{[1
]}

Moreira, Rui ^{[1
]}

机构：

[1] Univ Lisbon, Fac Farm, Res Inst Med iMed ULisboa, Ave Prof Gama Pinto, P-1649003 Lisbon, Portugal

[2] Univ Lisbon, Inst Super Tecn, CQE, Ave Rovisco Pais, P-1049001 Lisbon, Portugal

[3] Univ Porto, Fac Farm, Dept Ciencias Biol, LAQV REQUIMTE,Lab Microbiol, Rua Jorge Viterbo Ferreira 228, P-4050313 Porto, Portugal

来源：

FUTURE MEDICINAL CHEMISTRY | 2019年 / 11卷 / 15期

关键词：

blood-brain barrier; kinase inhibitors; kinase selectivity; LRRK2; LRRK2 G2019S mutation; inhibitors; neurodegeneration; Parkinson's disease; serine-threonine kinase; small molecule inhibitors; AUTOSOMAL-DOMINANT PARKINSONISM; BRAIN-PENETRANT; HIGHLY POTENT; INHIBITORS; DISCOVERY; MUTATION; GENE; BINDING; DESIGN; IDENTIFICATION;

D O I：

10.4155/fmc-2018-0484

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Leucine-rich repeat kinase 2 (LRRK2) is a serine-threonine kinase involved in multiple cellular processes and signaling pathways. LRRK2 mutations are associated with autosomal-inherited Parkinson's disease (PD), and evidence suggests that LRRK2 pathogenic variants generally increase kinase activity. Therefore, inhibition of LRRK2 kinase function is a promising therapeutic strategy for PD treatment. The search for drug-like molecules capable of reducing LRRK2 kinase activity in PD led to the design of selective LRRK2 inhibitors predicted to be within the CNS drug-like space. This review highlights the journey that translates chemical tools for interrogating the role of LRRK2 in PD into promising drug candidates, addressing the challenges in discovering selective and brain-penetrant LRRK2 modulators and exploring the structure-activity relationship of distinct LRRK2 inhibitors.

引用

页码：1953 / 1977

页数：25

共 79 条

[1] Novel Pathogenic LRRK2 p.Asn1437His Substitution in Familial Parkinson's Disease [J].

Aasly, Jan O. ;

Vilarino-Gueell, Carles ;

Dachsel, Justus C. ;

Webber, Philip J. ;

West, Andrew B. ;

Haugarvoll, Kristoffer ;

Johansen, Krisztina K. ;

Toft, Mathias ;

Nutt, John G. ;

Payami, Haydeh ;

Kachergus, Jennifer M. ;

Lincoln, Sarah J. ;

Felic, Amela ;

Wider, Christian ;

Soto-Ortolaza, Alexandra I. ;

Cobb, Stephanie A. ;

White, Linda R. ;

Ross, Owen A. ;

Farrer, Matthew J. .

MOVEMENT DISORDERS, 2010, 25 (13) :2156-2163

[2] Abnormal visual gain control in a Parkinson's disease model [J].

Afsari, Farinaz ;

Christensen, Kenneth V. ;

Smith, Garrick Paul ;

Hentzer, Morten ;

Nippe, Olivia M. ;

Elliott, Christopher J. H. ;

Wade, Alex R. .

HUMAN MOLECULAR GENETICS, 2014, 23 (17) :4465-4478

[3] LRRK2 kinase in Parkinson's disease [J].

Alessi, Dario R. ;

Sammler, Esther .

SCIENCE, 2018, 360 (6384) :36-37

[4] PFE-360-induced LRRK2 inhibition induces reversible, non-adverse renal changes in rats [J].

Andersen, Michael Aagaard ;

Wegener, Karen Malene ;

Larsen, Steen ;

Badolo, Lassina ;

Smith, Garrick Paul ;

Jeggo, Ross ;

Jensen, Poul Henning ;

Sotty, Florence ;

Christensen, Kenneth Vielsted ;

Thougaard, Annemette .

TOXICOLOGY, 2018, 395 :15-22

[5] LRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectives [J].

Atashrazm, Farzaneh ;

Dzamko, Nicolas .

CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2016, 8 :177-189

[6] Function and dysfunction of leucine-rich repeat kinase 2 (LRRK2): Parkinson's disease and beyond [J].

Bae, Jae Ryul ;

Lee, Byoung Dae .

BMB REPORTS, 2015, 48 (05) :243-248

[7] Exploring structural requirement, pharmacophore modeling, and de novo design of LRRK2 inhibitors using homology modeling approach [J].

Bhayye, Sagar S. ;

Roy, Kunal ;

Saha, Achintya .

MEDICINAL CHEMISTRY RESEARCH, 2014, 23 (08) :3705-3713

[8] Discovery of a Highly Selective, Brain-Penetrant Aminopyrazole LRRK2 Inhibitor [J].

Chan, Bryan K. ;

Estrada, Anthony A. ;

Chen, Huffen ;

Atherall, John ;

Baker-Glenn, Charles ;

Beresford, Alan ;

Burdick, Daniel J. ;

Chambers, Mark ;

Dominguez, Sara L. ;

Drummond, Jason ;

Gill, Andrew ;

Kleinheinz, Tracy ;

Le Pichon, Claire E. ;

Medhurst, Andrew D. ;

Liu, Xingrong ;

Moffat, John G. ;

Nash, Kevin ;

Scearce-Levie, Kimberly ;

Sheng, Zejuan ;

Shore, Daniel G. ;

Van de Poel, Herve ;

Zhang, Shuo ;

Zhu, Haitao ;

Sweeney, Zachary K. .

ACS MEDICINAL CHEMISTRY LETTERS, 2013, 4 (01) :85-90

[9] Discovery of Selective LRRK2 Inhibitors Guided by Computational Analysis and Molecular Modeling [J].

Chen, Huifen ;

Chan, Bryan K. ;

Drummond, Jason ;

Estrada, Anthony A. ;

Gunzner-Toste, Janet ;

Liu, Xingrong ;

Liu, Yichin ;

Moffat, John ;

Shore, Daniel ;

Sweeney, Zachary K. ;

Thuy Tran ;

Wang, Shumei ;

Zhao, Guiling ;

Zhu, Haitao ;

Burdick, Daniel J. .

JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (11) :5536-5545

[10] Brain Penetrant LRRK2 Inhibitor [J].

Choi, Hwan Geun ;

Zhang, Jinwei ;

Deng, Xianming ;

Hatcher, John M. ;

Patricelli, Matthew P. ;

Zhao, Zheng ;

Alessi, Dario R. ;

Gray, Nathanael S. .

ACS MEDICINAL CHEMISTRY LETTERS, 2012, 3 (08) :658-662

← 1 2 3 4 5 6 7 8 →